Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials DOI Creative Commons
Syed Nasir Abbas Bukhari

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(4), P. 866 - 866

Published: April 15, 2022

A key issue with modern cancer treatments is the emergence of resistance to conventional chemotherapy and molecularly targeted medicines. Cancer nanotherapeutics were created in order overcome inherent limitations traditional chemotherapeutics. Over last few decades, provided unparalleled opportunities understand drug through clinical assessment rationally designed nanoparticulate delivery systems. In this context, various design strategies such as passive targeting, active nano-drug, multimodal nano-drug combination therapy effective treatment. Even though nanotherapy has made great technological progress, tumor biology complexity heterogeneity a lack comprehensive knowledge nano-bio interactions remain important roadblocks future translation commercialization. The current developments advancements employing wide variety nanomaterial-based platforms treatment are discussed article. There also review nanotherapeutics-based approaches therapy, including targeting for microenvironment its components, advanced systems specific stem cells (CSC), well exosomes strategies, an update on trials. Finally, challenges perspective reverse discussed.

Language: Английский

Therapeutic strategies to overcome taxane resistance in cancer DOI
Tuyelee Das,

Uttpal Anand,

Swaroop Kumar Pandey

et al.

Drug Resistance Updates, Journal Year: 2021, Volume and Issue: 55, P. 100754 - 100754

Published: Feb. 27, 2021

Language: Английский

Citations

156
Novel nanomedicines to overcome cancer multidrug resistance DOI
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao

et al.

Drug Resistance Updates, Journal Year: 2021, Volume and Issue: 58, P. 100777 - 100777

Published: Aug. 4, 2021

Language: Английский

Citations

137
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook DOI Creative Commons
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 1796 - 1796

Published: June 23, 2023

Triple negative breast cancer (TNBC) has a expression of estrogen receptors (ER), progesterone (PR), and human epidermal growth factor (HER2). The survival rate for TNBC is generally worse than other subtypes. treatment made significant advances, but certain limitations remain. Treatment can be challenging since the disease various molecular A variety options are available, such as chemotherapy, immunotherapy, radiotherapy, surgery. Chemotherapy most common these options. treated with systemic chemotherapy using drugs anthracyclines taxanes in neoadjuvant or adjuvant settings. Developing resistance to anticancer off-target toxicity primary hindrances chemotherapeutic solutions cancer. It imperative that researchers, clinicians, pharmaceutical companies work together develop effective TNBC. Several studies have suggested nanotechnology potential solution problem suboptimal treatment. In this review, we summarized possible TNBC, including targeted therapy, combination nanoparticle-based some future. Moreover, gave general information about terms its characteristics aggressiveness.

Language: Английский

Citations

134
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors DOI Creative Commons
Xiaojing Du, Biwei Yang, Quanlin An

et al.

The Innovation, Journal Year: 2021, Volume and Issue: 2(2), P. 100103 - 100103

Published: April 3, 2021

The discovery that mutations in the EGFR gene are detected up to 50% of lung adenocarcinoma patients, along with development highly efficacious epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized treatment this frequently occurring malignancy. Indeed, clinical success these TKIs constitutes a critical milestone targeted cancer therapy. Three generations EGFR-TKIs currently approved for mutation-positive non-small cell (NSCLC). first-generation include erlotinib, gefitinib, lapatinib, and icotinib; second-generation ErbB family blockers afatinib, neratinib, dacomitinib; whereas osimertinib, by FDA on 2015, is third-generation TKI targeting harboring specific mutations. Compared first- TKIs, display significant advantage terms patient survival. For example, median overall survival NSCLC patients receiving osimertinib reached 38.6 months. Unfortunately, however, like other therapies, new mutations, as well additional drug-resistance mechanisms emerge rapidly after treatment, posing formidable obstacles therapeutics aimed at surmounting chemoresistance. In review, we summarize molecular underlying resistance ongoing efforts address overcome We also discuss current status fourth-generation inhibitors, which great value overcoming appear have greater therapeutic benefits clinic.

Language: Английский

Citations

114
Long non-coding RNA mediated drug resistance in breast cancer DOI
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche

et al.

Drug Resistance Updates, Journal Year: 2022, Volume and Issue: 63, P. 100851 - 100851

Published: July 1, 2022

Language: Английский

Citations

96
Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer DOI Open Access
Reyhaneh Farghadani, Rakesh Naidu

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(4), P. 2144 - 2144

Published: Feb. 15, 2022

Female breast cancer is the world’s most prevalent in 2020. Chemotherapy still remains a backbone therapy and crucial advanced metastatic treatment. The clinical efficiency of chemotherapy regimens limited due to tumor heterogeneity, chemoresistance, side effects. Chemotherapeutic drug combinations with natural products hold great promise for enhancing their anticancer efficacy. Curcumin an ideal chemopreventive agent owning its multitargeting function on various regulatory molecules, key signaling pathways, pharmacological safety. This review aimed elucidate potential role curcumin efficacy doxorubicin, paclitaxel, 5-fluorouracil, cisplatin via combinational therapy. Additionally, molecular mechanisms underlying chemosensitizing activity these have been addressed. Overall, based promising therapeutic combination conventional drugs, considerable value develop as adjunct current drugs treat cancer. Furthermore, this topic may provide frameworks future research direction curcumin–chemotherapy studies benefit development novel strategy maximize while minimizing effects

Language: Английский

Citations

81
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents DOI Creative Commons
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć

et al.

Drug Resistance Updates, Journal Year: 2022, Volume and Issue: 63, P. 100844 - 100844

Published: May 2, 2022

Selenium is an essential trace element that crucial for cellular antioxidant defense against reactive oxygen species (ROS). Recently, many selenium-containing compounds have exhibited a wide spectrum of biological activities make them promising scaffolds in Medicinal Chemistry, and, particular, the search novel with anticancer activity. Similarly, certain tellurium-containing also substantial activities. Here we provide overview seleno- and tellurocompounds including chemopreventive activity, or pro-oxidant modulation inflammatory processes, induction apoptosis, autophagy, inhibition multidrug efflux pumps such as P-gp, cancer metastasis, selective targeting tumors enhancement cytotoxic activity chemotherapeutic drugs, well overcoming tumor drug resistance. A review chemistry most relevant resistant cancers presented, paying attention to synthesis these preparation bioactive selenium tellurium nanoparticles. Based on data, use approach development strategies can drive forward therapies adjuvants current drug-resistant cancers.

Language: Английский

Citations

71
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria DOI Creative Commons
Xiaoqing Xie, Yi Yang, Qiang Wang

et al.

Cell Research, Journal Year: 2023, Volume and Issue: 33(3), P. 215 - 228

Published: Jan. 10, 2023

Abstract Only a small proportion of patients with triple-negative breast cancer benefit from immune checkpoint inhibitor (ICI) targeting PD-1/PD-L1 signaling in combination chemotherapy. Here, we discovered that therapeutic response to ICI plus paclitaxel was associated subcellular redistribution PD-L1. In our immunotherapy cohort nab-paclitaxel, tumor samples responders showed significant distribution PD-L1 at mitochondria, while non-responders increased accumulation on cell membrane instead mitochondria. Our results also revealed the pattern regulated by an ATAD3A-PINK1 axis. Mechanistically, PINK1 recruited mitochondria for degradation via mitophagy pathway. Importantly, ATAD3A expression disrupt proteostasis restraining PINK1-dependent mitophagy. Clinically, tumors exhibiting high detected before treatment had markedly shorter progression-free survival compared those ATAD3A-low tumors. Preclinical further demonstrated reset favorable antitumor microenvironment and efficacy therapy paclitaxel. summary, indicate serves not only as resistant factor through preventing mitochondrial distribution, but promising target increasing responses chemoimmunotherapy.

Language: Английский

Citations

59
Beyond matrix stiffness: targeting force-induced cancer drug resistance DOI Creative Commons
Maria Kalli, Matthew D. Poskus, Triantafyllos Stylianopoulos

et al.

Trends in cancer, Journal Year: 2023, Volume and Issue: 9(11), P. 937 - 954

Published: Aug. 8, 2023

During tumor progression, mechanical abnormalities in the microenvironment (TME) trigger signaling pathways cells that activate cellular programs, resulting growth and drug resistance. In this review, we describe mechanisms of action for anti-cancer therapies mechanotransduction programs regulate processes, including cell proliferation, apoptosis, survival phenotype switching. We discuss how therapeutic response is impacted by three main TME abnormalities: high extracellular matrix (ECM) composition stiffness; interstitial fluid pressure (IFP); elevated forces. also review drugs normalize these or block mechanosensors pathways. Finally, current challenges perspectives development new strategies targeting mechanically induced resistance clinic.

Language: Английский

Citations

53
Strategies and Lessons Learned from Total Synthesis of Taxol DOI
Long Min,

Jing‐Chun Han,

Wen Zhang

et al.

Chemical Reviews, Journal Year: 2023, Volume and Issue: 123(8), P. 4934 - 4971

Published: March 14, 2023

Taxol (paclitaxel), the most well-known taxane diterpenoid, is best-selling natural-source anticancer drug ever produced and one of common prescriptions in treatment breast, lung, ovarian cancers, saving countless lives around world. Structurally, possesses a highly oxygenated [6–8–6–4] core bearing 11 stereocenters, seven which are contiguous chiral centers. Moreover, extremely strained bicyclo[5.3.1] undecane ring system with bridgehead double bond unique structural feature. All these features make challenging synthetic target. Tremendous efforts from more than 60 research groups world have already culminated ten total syntheses three formal syntheses, as well model studies Taxol. This review intended to provide long-overdue appraisal great achievements reported last few decades. In doing so, we summarize development synthesis toward 1994 2022, including evolution strategy for accessing this complex molecular scaffold key lessons learned such endeavors. Finally, briefly discuss future area.

Language: Английский

Citations

46